title: CYP1A1 polymorphism interactions with smoking status in oral cancer risk: evidence from epidemiological studies.
abstract: The cytochrome CYP1A1 gene has been implicated in the etiology of oral cancer. However, the results have been inconsistent. In this study, a meta-analysis was performed to clarify the associations of polymorphisms in CYP1A1 gene with oral cancer risk. Published literatures from PubMed, MEDLINE, EMBASE, and China National Knowledge infrastructure (CNKI) databases were retrieved. A total of 12 studies were included in this meta-analysis. We found that significant positive associations between CYP1A1*2A polymorphism and oral cancer risk in recessive model (CC vs. TC + TT, OR = 1.93), dominant model (CC + TC vs. TT, OR = 1.33), and additive model (CC vs. TT, OR = 1.97). In subgroup analysis based on the ethnicity of study population, significant associations were found in all three genetic models for Asians (recessive OR = 2.29, 95% CI =  .42-3.71; dominant OR = 1.54, 95% CI = 1.03-2.31; additive OR  2.39, 95% CI = 1.47-3.88) but not non-Asians. For the smoking stratification, the result indicated a significant association between CYP1A1*2A polymorphism and oral cancer among the smoking subjects (OR = 1.83, 95% CI = 1.47-2.26). This meta-analysis indicated a marked association of CYP1A1*2A polymorphisms with oral cancer risk, particularly among Asians, whereas there were significant interactions between the polymorphisms and cigarette smoking on oral cancer risk.
authors.affiliation: Department of oral and maxillofacial surgery, The 307 Hospital of the Academy of Military Medical Sciences, Beijing, 100071, People's Republic of China.
authors.forename: Kai-Tao
authors.initials: KT
authors.lastname: Yu
authors.forename: Cheng
authors.initials: C
authors.lastname: Ge
authors.forename: Xiao-Fang
authors.initials: XF
authors.lastname: Xu
authors.forename: Jing-Cai
authors.initials: JC
authors.lastname: Zou
authors.forename: Xuan
authors.initials: X
authors.lastname: Zou
authors.forename: Shuai
authors.initials: S
authors.lastname: Zhen
mesh_terms: D016022:Case-Control Studies; D019363:Cytochrome P-450 CYP1A1 / Q000235:genetics*; D020022:Genetic Predisposition to Disease; D006801:Humans; D009062:Mouth Neoplasms / Q000209:etiology*; D011110:Polymorphism, Genetic / Q000235:genetics*; D011379:Prognosis; D012307:Risk Factors; D012907:Smoking / Q000009:adverse effects*
chemical_list: C569463:CYP1A1 protein, human; D019363:Cytochrome P-450 CYP1A1
references.citation: Oral Oncol. 2001 Oct;37(7):593-8
references.pmid: 11564581
references.citation: Genet Mol Biol. 2012 Apr;35(2):407-12
references.pmid: 22888287
references.citation: Ann Intern Med. 2011 Oct 18;155(8):529-36
references.pmid: 22007046
references.citation: Yonsei Med J. 2007 Apr 30;48(2):233-9
references.pmid: 17461521
references.citation: Mutat Res. 1998 May 25;400(1-2):201-13
references.pmid: 9685642
references.citation: Am J Hum Genet. 1991 Apr;48(4):720-5
references.pmid: 1707592
references.citation: BMJ. 1997 Sep 13;315(7109):629-34
references.pmid: 9310563
references.citation: Oral Dis. 2003 Mar;9(2):62-7
references.pmid: 12657030
references.citation: Head Neck. 2006 Sep;28(9):819-26
references.pmid: 16721740
references.citation: J Clin Epidemiol. 2009 Oct;62(10):1006-12
references.pmid: 19631508
references.citation: J Natl Cancer Inst. 1959 Apr;22(4):719-48
references.pmid: 13655060
references.citation: Control Clin Trials. 1986 Sep;7(3):177-88
references.pmid: 3802833
references.citation: Mol Biol Rep. 2012 Apr;39(4):3533-40
references.pmid: 21710246
references.citation: Stat Med. 2002 Jun 15;21(11):1539-58
references.pmid: 12111919
references.citation: Mutat Res. 2011 Jul-Oct;728(1-2):67-79
references.pmid: 21708280
references.citation: J Oral Pathol Med. 2002 Oct;31(9):505-11
references.pmid: 12269988
references.citation: Head Neck Oncol. 2011 Jan 06;3:2
references.pmid: 21211041
references.citation: Breast Cancer Res Treat. 2010 Jul;122(2):459-69
references.pmid: 20035380
references.citation: J Oral Pathol Med. 2008 Oct;37(9):511-4
references.pmid: 18624933
references.citation: PLoS One. 2014 Feb 05;9(2):e88240
references.pmid: 24505444
references.citation: JAMA. 2000 Apr 19;283(15):2008-12
references.pmid: 10789670
references.citation: Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2012 Sep;156(3):253-9
references.pmid: 22660220
references.citation: Oral Dis. 2014 Jan;20(1):84-93
references.pmid: 23444898
references.citation: Am J Epidemiol. 2005 May 15;161(10):901-15
references.pmid: 15870154
references.citation: Oncol Lett. 2010 May;1(3):549-553
references.pmid: 22966341
references.citation: Carcinogenesis. 2007 Jul;28(7):1455-62
references.pmid: 17307803
references.citation: Int J Oncol. 2008 May;32(5):945-73
references.pmid: 18425322
references.citation: Mutagenesis. 2011 May;26(3):437-46
references.pmid: 21402622
references.citation: Cancer Invest. 2012 Oct;30(8):552-9
references.pmid: 22909097
references.citation: Am J Epidemiol. 1992 May 1;135(9):1029-41
references.pmid: 1595689
references.citation: Urol J. 2009 Spring;6(2):78-86
references.pmid: 19472123
references.citation: Hua Xi Kou Qiang Yi Xue Za Zhi. 2012 Apr;30(2):187-91
references.pmid: 22594240
references.citation: Cancer Epidemiol Biomarkers Prev. 2000 Oct;9(10):1119-22
references.pmid: 11045797
references.citation: Oral Oncol. 1999 Mar;35(2):191-6
references.pmid: 10435155
references.citation: Clin Chem. 2003 Jan;49(1):1-6
references.pmid: 12507953
references.citation: Indian J Clin Biochem. 2010 Jul;25(3):260-72
references.pmid: 21731197
references.citation: Anticancer Res. 2008 Mar-Apr;28(2A):1023-8
references.pmid: 18507050